Ocular preservatives: Associated risks and newer

Cutaneous and Ocular Toxicology

Volumn 28, Issue 3, 2009, Pages 93-103

  Kaur, Indu Pal ^a   Lal, Shruti ^a   Rana, Cheena ^a   Kakkar, Shilpa ^a   Singh, Harinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Newer; Ocular; Preservative; Toxicity

Indexed keywords

ASCORBIC ACID; BENZALKONIUM CHLORIDE; BION; BLINK GEL TEARS LUBRICATING EYE DROPS; CHLORBUTOL; CHLORHEXIDINE ACETATE; CHLORINE DERIVATIVE; CHLOROCRESOL; DETERGENT; DRUG PRESERVATIVE; EYE DROPS; GENTEAL; HYDROXYBENZOIC ACID DERIVATIVE; HYDROXYPROPYLCELLULOSE; HYPO TEARS; ISOPTO; LACRI LUBE; METHYL PARABEN; MINIDROPS EYE THERAPY; MURINE TEARS LUBRICANT EYE DROPS; MURINE TEARS PLUS LUBRICANT REDNESS RELIEVER EYE DROPS; MUROCEL; OPTIVE; OXIDIZING AGENT; OXYCHLORO COMPLEX; PERBORATE SODIUM; PHENETHYL ALCOHOL; PHENYLMERCURIC ACETATE; PHENYLMERCURIC NITRATE; POLY(HEXAMETHYLENEBIGUANIDE); POLYQUATERNIUM 1; PRESERVATIVE FREE MOISTURE EYES; PROPYL PARABEN; PURALUBE; REFRESH; ROHTO V ARCTIC; SODIUM DERIVATIVE; SOOTHE; SYSTANE; TEARS RENEWED; TETRYZOLINE; THERATEARS; THIOMERSAL; TRAVOPROST; UNCLASSIFIED DRUG;

DRUG INSTILLATION; DRUG SAFETY; DRY EYE; EYE TOXICITY; HUMAN; NONHUMAN; REVIEW; SUSTAINED RELEASE FORMULATION;

CELLS, CULTURED; EPITHELIAL CELLS; EYE; HUMANS; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; RISK; TOXICITY TESTS;

EID: 70350676860     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.1080/15569520902995834     Document Type: Review

References (68)

1. Noecker R. Ophthalmic preservatives: Considerations for longterm use in patients with dry eye or glaucoma. Rev Ophthalmol 2001; 8:73-79. http://www.revophth.com/2001/june/cme0601-article.htm
2. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205-215.
3. Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974; 7(1):98-105.
4. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 1980; 32:2259-2265.
5. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc 1985; 104(Pt 4):402-409.
6. Champeau EJ, Edellhauser HF. Effects of ophthalmic preservatives on the ocular surface: Conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly FJ, Lamberts D, Mac Keen D, eds. The Preocular Tear Film in Health, Disease, and Contact Lens Wear; Lubbock, TX: Dry Eye Institute. 1998:292-302.
7. Gassett AR. Benzalkonium chloride toxicity to the human cornea. Am J Ophthalmol 1977; 84(2):169-171.
8. Fisher AA. Allergic contact dermatitis and conjunctivitis from benzalkonium chloride. Cutis 1987; 3(5):381-383.
9. Goh CL. Contact sensitivity to topical antimicrobials, II: Sensitizing potentials of some topical antimicrobials. Contact Dermatitis 1989; 21(3):166-171.
10. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994; 101:454-460.
11. Baudouin C, Pisella PJ, Goldschild M. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 105:556-563.
12. Anders N, Wollensak J. Ocular pseudopemphigoid after topical drug administration. Klin Monatsbl Augenheilkd 1994; 205(2):61-64.
13. Kuppens EV, De Jong CA, Stolwijk TR, De Kreizer RJ, Van Best JA. Effects of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol 1995; 79:339-342.
14. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992; 99:873-878.
15. Broadway DC, Grierson I, Hitchings RA. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 1993; 77:590-596. (Pubitemid 23281461)
16. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medications, I: The conjunctival cell profile. Arch Ophthalmol 1994; 112:1437-1445. (Pubitemid 24350506)
17. Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990; 108:1543-1550.
18. Young TL, Higginbotham EJ, Zou X, Farbe MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 1990; 97:1423-1427.
19. Samples JR, Binder S, Nayak S. The effects of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res 1989; 49(1):1-12.
20. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxicity Res 1992; 9(3-4):361-375.
21. Shaw AJ, Balls M, Clothier RH, Bateman ND. Predicting ocular irritancy and recovery from injury using Madin-Darby canine kidney cells. Toxicol In Vitro 1991; 5:169-174.
22. Takahashi N. Cytotoxicity of mercurial preservatives in cell culture. Ophthalmic Res 1982; 14(1):63-69.
23. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40:619-630.
24. Debbasch C, De Saint Jean M, Pisella PJ, Rat P, Warnet JM, Baudouin C. Evaluation of toxicity of preservative-free and preserved beta-blockers in a human conjunctival cell line. Invest Ophthalmol Vis Sci 1999; 40:8(4):5825.
25. Debbasch C, De Saint Jean M, Pisella PJ, Rat P, Warnet JM, Baudouin C. Influence of preservatives on conjunctival cells in vitro. J Toxicol Cutan Ocul Toxicol 2000; 19:79-88. www.informaworld.com.
26. Kreiner C. Biochemical aspects of ophthalmic preservatives. Contacto 1979; Nov:10-14.
27. Grant WM, Schuman JS. In: Grant WM, ed. Toxicology of the Eye. 4th ed; Springfield, IL: Charles C Thomas Publishers Ltd, 1993:167-169.
28. Block SS. Definition of terms. In: Block SS, ed. Disinfection, Sterilization, and Preservation. 4th ed; Malvern, PA: Lea & Febiger Publishers, 1991:18-25.
29. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol 1992; 110:528-532.
30. Burstein, NL, Klyce SD. Electrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epithelium. Invest Ophthalmol Vis Sci 1977; 6:899-911.
31. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998; 82(1):39-42.
32. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma \topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000; 20(2):85-94. (Pubitemid 30099159)
33. Holly FJ. Surface chemical evaluation of artificial tears and their ingredients. II. Interaction with a superficial lipid layer. Contact and Intraocular Lens Medical Journal 1978, 4(3):62-65.
34. Kuppens EV, van Best JA, Sterk CC, de Keizer R. Decreased basal tear turnover in patients with untreated primary open-angle glaucoma. Am J Ophthalmol 1995; 120(1):41-46.
35. Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000; 32(1):3-8.
36. Campagna P, Macri A, Rolando M, Calabria G. Chronic topical eye preservative-free beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol Scand 1997; 75(224):53.
37. Yalvac IS, Gedikoglu G, Karagoz Y. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995; 73:246-248.
38. Turacli E, Budak K, Kaur A, Mizrak B, Ekinci C. The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997; 21(1):27-33.
39. Pflugfelder SC, Huang AJW, Schuclovski PT, Pereira IC, Tseng SCG. Conjunctival cytological features of primary Sjogren's syndrome. Ophthalmology 1990; 97:985-991.
40. http://www.reuters.com/article/pressRelease/idUS129178+06-Apr- 009+PRN20090406. Accessed April 2009.
41. Freeman PD, Kahook MK. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Exp Rev Ophthalmol 2009; 4:59-64. http://www.medscape.com/ viewarticle/588636.
42. Epstein EP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009; 25:113-119.
43. Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol 2000; 28:113-117.
44. Kohn SR, Gershenfeld L, Barr M. Effectiveness of antibacterial agents presently employed in ophthalmic preparations as preservatives against Pseudomonas aeruginosa. J Pharm Sci 1963; 52:967-974.
45. Riegelman S, Vaughan DG Jr, Okumoto M. Antibacterial agents in Pseudomonas aeruginosa contaminated ophthalmic solution. J Am Pharm Assoc (Baltim) 1956; 45(2 part 1):93-98. http:// www.ncbi.nlm.nih.gov/pubmed/13295113.
46. Cooper JW, Gunn C. Ophthalmic products. In: Carter SL, ed. Dispensing for Pharmaceutical Students. 12th ed; Delhi, India: CBS Publisher and Distributors. 2000:634-662.
47. Linton KB, George E. Inactivation of chlorhexidine (Hibitane) by bark corks. Lancet 1966; 1(7451):1353-1355.
48. Tomlinson A, Trees GR. Effect of preservatives in artificial tear solutions on tear film evaporation. Ophthalmic Physiol Opt 1991; 11(1):48-52.
49. Fassihi AR, Naidoo NT. Irritation associated with tear- replacement ophthalmic drops. A pharmaceutical and subjective investigation. S Afr Med J 1989; 75:233-235.
50. Tripathi BJ, Tripathi RC. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res 1989; 6(3):395-403.
51. Lazarus HM, Imperia PS, Botti RE, Mack RJ, Lass JH. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Lens Eye Toxic Res 1989; 6(1-2):59-85.
52. Lopez B, Ubel J. Quantitative evaluation of the corneal epithelial barrier: Effect of artificial tears and preservatives. Curr Eye Res 1991; 10:7645-7656.
53. Labbe A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM, Baudouin C. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: An experimental study. J Ocul Pharmacol Ther 2006; 22:267-278.
54. Abelson MB, Udell IJ. Conjunctiva, cornea, and sclera. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd ed; Philadelphia, PA: W.B. Saunders. 2000.
55. Grant R, Ajello M, Vlass E. Salt water or high tech? A look at two new rinsing solutions for contact lenses. Optician 1996; 212: 38-41. http://www.medscape.com/viewarticle/588636.
56. Vaughan JS, Porter DA. A new in vitro method for assessing the potential toxicity of soft contact lens care solutions. CLAO J 1993; 19(1):54-57.
57. Paugh JR, Brennan NA, Efron N. Ocular response to hydrogen peroxide. Am J Optom Physiol Opt 1988; 65(2):91-98.
58. Seiler JP. The mutagenic activity of sodium perborate. Mutat Res 1989; 224(2):219-227.
59. Masschelein WJ, Rice RG. Chlorine dioxide. In: Masschelein WJ, Rice RG, eds. Chemistry and Environmental Impact of Oxychlorine Compounds; Ann Arbor, MI: Ann Arbor Science Publishers Inc. 1979:5-7.
60. Purite, package insert. Norman, OK: Bio-Cide International Inc. 1998:1-3.
61. Rozen S, Abelson M, Giovanoni A, Welch D. Assessment of the comfort and tolerance of 0.5% carboxymethylcellulose preserved with Purite (Refresh Tears) in dry eye sufferers. Invest Ophthalmol Vis Sci 1998; 39:(4):S451.
62. Way WA, Matsumoto S, Apel LJ, Wiese A, Tarlo K, Vehige J. Purite as a non-disruptive preservative for lubricating eye drop solutions in comparison to alternative preservatives. Presented at the Association for Research in Vision and Ophthalmology (ARVO), 2001 and published abstract reference: Invest Ophthalmol Vis Sci 2001; 42(4):S39.
63. Pham XT, Huff JW. Cytotoxicity evaluation of multipurpose contact lens solutions using an in vitro test battery. CLAO J 1999; 25(1):28-35.
64. Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: Future perspective in topical glaucoma therapeutics. Int J Pharm 2002; 248(1-2):1-14.
65. Kahook MY. Travoprost Z. Ophthalmic solution with sofZia: Clinical safety and efficacy. Exp Rev Ophthalmol 2007; 2:363-368.
66. Lewis RA, Katz G, Weiss MJ. Travoprost 0.004% with and without benzalkonium chloride: A comparison of safety and efficacy. J Glaucoma 2007; 16(1):98-103.
67. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without BAK and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006; 23:511-518.
68. Whitson JT, Cavanaugh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity following acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23:663-671.